¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Accuracy in the Staging of Non-Small Cell Lung Cancer: Review and Cost-Effectiveness

Table 1

Variables used in the cost-effectiveness analysis.

Variable	Value	Lower limit	Upper limit	Source
Sensitivity of mediastinoscopy	0.72	0.63	0.81	[6, 7]
Specificity of PET	0.50	0.40	0.60	Present study
Specificity of CT	0.72	0.63	0.81	Present study
Specificity of PET/CT	0.82	0.75	0.89	Present study
Sensitivity of PET/CT	0.94	0.89	0.99	Present study
Sensitivity of PET	0.60	0.51	0.69	Present study
Sensitivity of CT	0.72	0.63	0.81	Present study
Prevalence	0.61	0.52	0.71	Present study
Costs
Surgery cost	9917.83	7934.26	11901.37	DRG SNS [8]
PET cost	1091	872.8	1309.2	DRG CM [9]
PET/CT cost	1290	400	1500	DRG CM [9]
Radio + chemo cost	12807.33	10245.86	15368.80	DRG SNS [8]
CT cost	199	159.2	238.8	DRG CM [9]
Mediastinoscopy cost	4043.06	3234.44	4851.67	DRG SNS [8]
Outcomes
Life expectancy after surgery	7.85	4.5	11.20	[10]
Life expectancy after radiotherapy	3.50	1.80	5.20	[10]
U after curative surgery	0.88	0.82	0.94	[6, 11]
U during surgery recovery period	−0.15	−0.30	0	[6, 11]
U with progressive disease	0.473	0.273	0.673	[12, 13]
U after palliative radiotherapy	0.673	0.65	0.70	[12, 13]

PET = positron emission tomography; CT = computed tomography; DRG = disease-related group; SNS = Spanish National Health system; CM = ‘‘Comunidad de Madrid’’ (Autonomous Region of Madrid); U = patient-valued utility with respect to disease stage.